| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.TP.0000261113.30757.D1 |
| P698 | PubMed publication ID | 17496547 |
| P50 | author | Nassim Kamar | Q49264830 |
| P2093 | author name string | Dominique Durand | |
| Stanislas Faguer | |||
| Lionel Rostaing | |||
| David Ribes | |||
| Anne Modesto | |||
| Olivier Cointault | |||
| Marylise Fort | |||
| Joelle Guitard | |||
| Laurence Lavayssière | |||
| Arnaud Mari | |||
| Céline Guilbeaud-Frugier | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| kidney transplantation | Q740909 | ||
| P304 | page(s) | 1277-1280 | |
| P577 | publication date | 2007-05-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Rituximab therapy for acute humoral rejection after kidney transplantation | |
| P478 | volume | 83 |
| Q38228333 | A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection |
| Q39130806 | A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. |
| Q39105369 | Acute antibody-mediated rejection in kidney transplant recipients |
| Q83774038 | Acute antibody-mediated rejection in paediatric renal transplant recipients |
| Q37676032 | Advances in diagnosing and managing antibody-mediated rejection |
| Q37698860 | Antibody-Mediated Rejection: A Review |
| Q37647235 | Antibody-mediated rejection after adult living-donor liver transplantation triggered by positive lymphocyte cross-match combination |
| Q35915453 | Antibody-mediated rejection in kidney transplantation: a review |
| Q38392458 | Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management |
| Q42553965 | Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes |
| Q37332696 | Antibody-mediated rejection: treatment alternatives and outcomes. |
| Q38062614 | Antibody-mediated vascular rejection of kidney allografts: a population-based study |
| Q42929012 | B-cell depletion improves islet allograft survival with anti-CD45RB. |
| Q42038591 | B-cell tolerance in transplantation: is repertoire remodeling the answer? |
| Q34159016 | B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. |
| Q37820338 | Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach |
| Q83627899 | Bortezomib is effective to treat acute humoral rejection after liver transplantation |
| Q43239536 | Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. |
| Q38426194 | Characterization of intra-graft B cells during renal allograft rejection |
| Q37058050 | Chronic alloantibody mediated rejection |
| Q37626123 | Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. |
| Q38163419 | Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis |
| Q93188012 | Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients |
| Q88643834 | Complications of therapeutic apheresis in pediatric kidney transplantation |
| Q36752176 | Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection |
| Q79815538 | Cross Reactive Epitope Group antibodies in sensitized kidneys transplant recipients was associated with early acute Antibody Mediated Rejection |
| Q26829789 | Current state of renal transplant immunosuppression: Present and future |
| Q47172094 | De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases? |
| Q46045914 | Diagnosis and treatment of acute humoral kidney allograft rejection. |
| Q58805821 | Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians |
| Q37267474 | Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation |
| Q51955356 | Effects of B cell depletion on T cell allogeneic immune responses: a strategy to reduce allogeneic sensitization. |
| Q43906723 | High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis |
| Q43150813 | Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection |
| Q36028067 | Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group. |
| Q38044851 | Indications for use and safety of rituximab in childhood renal diseases |
| Q35664634 | Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin |
| Q40075357 | Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease |
| Q37161921 | Influence of plasma exchange on rituximab pharmacokinetics |
| Q27006030 | Late and chronic antibody-mediated rejection: main barrier to long term graft survival |
| Q88087346 | Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil |
| Q87213549 | Mannose-binding lectin-2 and ficolin-2 gene polymorphisms and clinical risk factors for acute rejection in kidney transplantation |
| Q37424651 | Mechanism of cellular rejection in transplantation |
| Q33891669 | Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model. |
| Q38176005 | Novel immunosuppressive agents in kidney transplantation |
| Q37058039 | Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. |
| Q42439336 | Plasma exchange and intravenous immunoglobulin in the treatment of antibody-mediated rejection after kidney transplantation: a single-center historic cohort study |
| Q34124202 | Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation |
| Q33783017 | Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab |
| Q35659332 | Recent advances in renal transplantation: antibody-mediated rejection takes center stage |
| Q82861887 | Rituximab in the treatment of acute cellular rejection of renal allograft with CD20-positive clusters in the infiltrate |
| Q37241071 | Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience |
| Q54979506 | SYK Inhibition Induces Apoptosis in Germinal Center-Like B Cells by Modulating the Antiapoptotic Protein Myeloid Cell Leukemia-1, Affecting B-Cell Activation and Antibody Production. |
| Q37710374 | Sensitized renal transplant recipients: current protocols and future directions |
| Q37531824 | The Effect of Histological CD20-Positive B Cell Infiltration in Acute Cellular Rejection on Kidney Transplant Allograft Survival |
| Q39254100 | The effect of histopathologic and clinical features on allograft survival in renal transplant patients with antibody-mediated rejection |
| Q37690953 | The yin and yang of B cells in graft rejection and tolerance |
| Q42849688 | Treatment of Acute Antibody-Mediated Rejection: A Single-Center Experience |
| Q37715187 | Updated principles and clinical caveats in the management of infection in renal transplant recipients |
| Q82564740 | [Antibody-mediated acute rejection] |
| Q81784352 | [Post-transplantation anti-HLA antibodies: which relevance?] |
| Q82564747 | [Role of anti-HLA antibodies whether or not they are directed against the donor during chronic renal graft dysfunction] |
Search more.